K. Quinn

发表

BHIVA – BASHH Position Statement on PrEP in UK Second Update May 2016

A. Nardone, S. McCormack, A. Phillips, 2016 .

Genetic Variants of APOL1 Are Major Determinants of Kidney Failure in People of African Ancestry With HIV

Hongbo Deng, A. Winston, C. Sabin, 2022, Kidney international reports.

Sickle Cell Trait and Kidney Disease in People of African Ancestry With HIV

Hongbo Deng, A. Winston, C. Sabin, 2021, Kidney international reports.

BHIVA/BASHH guidelines on the use of HIV pre–exposure prophylaxis (PrEP) 2018

S. McCormack, N. Field, A. Rodger, 2019, HIV medicine.

Laboratory adverse events and discontinuation of therapy according to CD4+ cell count at the start of antiretroviral therapy

C. Leen, C. Sabin, M. Johnson, 2014, AIDS.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study

R. Horne, A. Nardone, S. McCormack, 2017, PloS one.

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes

S. McCormack, D. Montefiori, J. Weber, 2017, Front. Immunol..

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

B. Gazzard, D. Webster, C. Leen, 2015, HIV medicine.

Antiretroviral Therapy – Nucleoside/Nucleotide and Non-Nucleoside Reverse Transcriptase Inhibitors

K. Quinn, Timothy Appleby, 2021, Encyclopedia of Virology.

A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol

R. Cortese, A. Nicosia, V. Libri, 2017, Scientific Reports.

BHIVA/BASHH guidelines on the use of HIV pre–exposure prophylaxis (PrEP) 2018

S. McCormack, N. Field, A. Rodger, 2019, HIV medicine.